AlgoTherapeutix Appoints Edmund Harrigan and Scott Byrd to the Board of Directors finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Share:
Exicure, Inc. (NASDAQ:XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced the appointments of Elizabeth (Betsy) Garofalo, M.D. and Mr. Andrew Sassine to its Board of Directors. We are pleased to welcome Betsy and Andrew to our Board at a critical time for Exicure, having made significant progress with the development of cavrotolimod in oncology and XCUR-FXN in Friedreich s ataxia. Betsy s distinguished career and significant clinical development experience and Andrew s financial and institutional investor experience will provide important perspective to our Board, said Timothy P. Walbert, Exicure s Chairman of the Board of Directors. We look forward to the collective experience they will bring as Exicure advances its pipeline of innovative investigational therapies and we look to deliver on the promise of Exicure s proprietary Spherical Nucleic Acid, or SNA technology.